The transaction – first announced in February – would see Novo Nordisk's parent company Novo Holdings buy contract development and manufacturing organisation (CDMO) Catalent outright for $16.5 ...
Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback